Linden Thomas Advisory Services LLC Has $851,000 Stock Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Linden Thomas Advisory Services LLC grew its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 3.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,456 shares of the company’s stock after acquiring an additional 225 shares during the period. Linden Thomas Advisory Services LLC’s holdings in Neurocrine Biosciences were worth $851,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in NBIX. Assenagon Asset Management S.A. grew its holdings in Neurocrine Biosciences by 120.6% in the 3rd quarter. Assenagon Asset Management S.A. now owns 584,539 shares of the company’s stock valued at $65,761,000 after buying an additional 319,564 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Neurocrine Biosciences by 73.0% in the 3rd quarter. Westfield Capital Management Co. LP now owns 649,292 shares of the company’s stock worth $73,045,000 after purchasing an additional 273,952 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in Neurocrine Biosciences by 59.0% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 692,374 shares of the company’s stock valued at $77,892,000 after purchasing an additional 256,920 shares during the period. Jennison Associates LLC grew its position in shares of Neurocrine Biosciences by 86.0% during the 3rd quarter. Jennison Associates LLC now owns 409,475 shares of the company’s stock worth $46,066,000 after purchasing an additional 189,345 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC raised its position in shares of Neurocrine Biosciences by 81.9% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 410,103 shares of the company’s stock valued at $54,035,000 after buying an additional 184,660 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on NBIX. Mizuho raised their price objective on Neurocrine Biosciences from $116.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, February 8th. Wells Fargo & Company raised shares of Neurocrine Biosciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $140.00 to $170.00 in a research report on Wednesday. The Goldman Sachs Group upped their price target on shares of Neurocrine Biosciences from $134.00 to $153.00 and gave the stock a “buy” rating in a report on Thursday, January 25th. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $148.00 to $158.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $147.00 price objective on shares of Neurocrine Biosciences in a research note on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Neurocrine Biosciences has a consensus rating of “Moderate Buy” and an average target price of $142.38.

Insider Transactions at Neurocrine Biosciences

In related news, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now directly owns 40,778 shares in the company, valued at approximately $5,438,154.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Eric Benevich sold 19,818 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $133.36, for a total value of $2,642,928.48. Following the sale, the insider now owns 40,778 shares of the company’s stock, valued at $5,438,154.08. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Ingrid Delaet sold 200 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $140.00, for a total transaction of $28,000.00. Following the completion of the transaction, the insider now directly owns 7,507 shares of the company’s stock, valued at $1,050,980. The disclosure for this sale can be found here. In the last 90 days, insiders sold 186,994 shares of company stock worth $25,806,409. 4.40% of the stock is owned by company insiders.

Neurocrine Biosciences Stock Down 0.9 %

NBIX opened at $137.76 on Friday. Neurocrine Biosciences, Inc. has a twelve month low of $89.04 and a twelve month high of $148.37. The company’s 50-day moving average price is $136.56 and its two-hundred day moving average price is $127.69. The stock has a market cap of $13.71 billion, a price-to-earnings ratio of 56.93 and a beta of 0.25.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings data on Wednesday, February 7th. The company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.31. Neurocrine Biosciences had a return on equity of 12.85% and a net margin of 13.23%. The business had revenue of $515.20 million during the quarter, compared to analyst estimates of $518.52 million. During the same period in the prior year, the company earned $0.88 earnings per share. Neurocrine Biosciences’s revenue was up 25.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Neurocrine Biosciences, Inc. will post 4.84 earnings per share for the current year.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.